{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:11:16Z","timestamp":1790701876429,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2025.108801","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:16:03Z","timestamp":1760998563000},"page":"108801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3317-8146","authenticated-orcid":false,"given":"Jiesong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-042X","authenticated-orcid":false,"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108801_b0035","doi-asserted-by":"crossref","unstructured":"Addeo, Alfredo et al. \u201cTarlatamab: a potential new option for recurrent small cell lung cancer.\u201d Translational lung cancer research vol. 12,7 (2023): 1628-1630. doi:10.21037\/tlcr-23-215.","DOI":"10.21037\/tlcr-23-215"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108801_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35770","article-title":"Top advances of the year: small cell lung cancer","volume":"131","author":"Shields","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108801_b0060","doi-asserted-by":"crossref","unstructured":"Kim, So Yeon et al. \u201cSmall Cell Lung Cancer: A Review.\u201d JAMA, 10.1001\/jama.2025.0560. 31 Mar. 2025, doi:10.1001\/jama.2025.0560.","DOI":"10.1001\/jama.2025.0560"},{"key":"10.1016\/j.lungcan.2025.108801_b0010","doi-asserted-by":"crossref","unstructured":"Paz-Ares, Luis et al. \u201cTarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.\u201d Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 41,16 (2023): 2893-2903. doi:10.1200\/JCO.22.02823.","DOI":"10.1200\/JCO.22.02823"},{"key":"10.1016\/j.lungcan.2025.108801_b0040","doi-asserted-by":"crossref","unstructured":"Tarlatamab Shows Promise in SCLC. Cancer discovery vol. 13,12 (2023): 2494. doi:10.1158\/2159-8290.CD-NB2023-0081.","DOI":"10.1158\/2159-8290.CD-NB2023-0081"},{"key":"10.1016\/j.lungcan.2025.108801_b0005","doi-asserted-by":"crossref","unstructured":"Ahn, Myung-Ju et al. \u201cTarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.\u201d The New England journal of medicine vol. 389,22 (2023): 2063-2075. doi:10.1056\/NEJMoa2307980.","DOI":"10.1056\/NEJMoa2307980"},{"key":"10.1016\/j.lungcan.2025.108801_b0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108801_b0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2025.108801_b0050","doi-asserted-by":"crossref","unstructured":"Crescioli, Silvia et al. \u201cAntibodies to watch in 2025.\u201d mAbs vol. 17,1 (2025): 2443538. doi:10.1080\/19420862.2024.2443538.","DOI":"10.1080\/19420862.2024.2443538"},{"key":"10.1016\/j.lungcan.2025.108801_b0020","doi-asserted-by":"crossref","unstructured":"Shrestha, Prajwol et al. \u201cCirculating tumor cells: advancing personalized therapy in small cell lung cancer patients.\u201d Molecular oncology, 10.1002\/1878-0261.13696. 2 Jul. 2024, doi:10.1002\/1878-0261.13696.","DOI":"10.1002\/1878-0261.13696"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108801_b0025","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.21037\/tlcr-23-115","article-title":"Tarlatamab: the promising immunotherapy on its way from the lab to the clinic","volume":"12","author":"Tang","year":"2023","journal-title":"Trans. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108801_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.989405","article-title":"Harnessing DLL3 inhibition: from old promises to new therapeutic horizons","volume":"9","author":"Cortinovis","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.lungcan.2025.108801_b0065","doi-asserted-by":"crossref","unstructured":"Kong, Stephanie et al. \u201cPopulation Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer.\u201d Clinical pharmacokinetics vol. 64,5 (2025): 729-741. doi:10.1007\/s40262-025-01499-z.","DOI":"10.1007\/s40262-025-01499-z"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108801_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104538","article-title":"Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy","volume":"10","author":"Chiang","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108801_b0070","unstructured":"U.S. Food and Drug Administration, Label of IMDELLTRA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761344s000lbl.pdf, 2024 (accessed 13 April 2025)."},{"key":"10.1016\/j.lungcan.2025.108801_b0075","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.lungcan.2025.108801_b0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","article-title":"Anti-tumor necrosis factoralpha therapy and hypoglycemia: a real-world pharmacovigilance analysis","volume":"45","author":"Zhou","year":"2022","journal-title":"Drug Saf."},{"key":"10.1016\/j.lungcan.2025.108801_b0085","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","article-title":"Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French PharmacoVigilance Database","volume":"72","author":"Chavant","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.lungcan.2025.108801_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200225010-00002","article-title":"Case-population studies in pharmacoepidemiology","volume":"25","author":"Capell\u00e0","year":"2002","journal-title":"Drug Saf."},{"key":"10.1016\/j.lungcan.2025.108801_b0095","article-title":"Drug-induced fall risk in older patients: a pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2025.108801_b0100","doi-asserted-by":"crossref","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623\u2013625.18. Berlin C, Blanch C, Lewis DJ, et al. Are all quantitative postmarketing signal.","DOI":"10.2165\/00002018-200730070-00011"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108801_b0105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","article-title":"Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in vigibase","volume":"43","author":"Sandberg","year":"2020","journal-title":"Drug Saf."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108801_b0130","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108801_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108801_b0110","doi-asserted-by":"crossref","unstructured":"Bolte, Fabian J et al. \u201cReal-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.\u201dClinical lung cancer, S1525-7304(25)00052-X. 26 Mar. 2025, doi:10.1016\/j.cllc.2025.03.006.","DOI":"10.2139\/ssrn.5100803"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:46:41Z","timestamp":1790700401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":25,"alternative-id":["S0169500225006932"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108801","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108801"}}